source
- Amgen's daxdilimab shows 6-point CLASI-A reduction in phase 2 lupus trialAmgen reported data from its phase 2 study of the ILT7-targeting monoclonal antibody daxdilimab in patients with discoid lupus. The trial enrolled 72 patients and tested two dose levels. The lower…
- FDA seeks new advisory committee members, signaling renewed focus on external expertiseThe FDA announced it is inviting subject‑matter experts and consumer representatives to serve on its advisory committees. The call follows a period when the advisory committees had a reduced role…